apoptosis inducer

Apoptosisinducer 26 (compound [AgCl(dap2SH)(PPh3)2]) is a mononuclear Ag(I) ligand-based autophagy inducer that exhibits antibacterial and anticancer activities against various bacterial strains and cancer cell lines. This compound facilitates the accumulation of Ag(I) ions in the periphery of bacteria, effectively inhibiting the growth of both Gram-positive (+) and Gram-negative (-) bacteria. Additionally, Apoptosisinducer 26 can intercalate between the base pairs of CT DNA, inducing apoptosis in A549 cells. It also possesses radical scavenging properties, which helps prevent oxidative stress.

Apoptosisinducer 28 (Compound X1) is an apoptosis inducer with demonstrated in vitro anticancer activity. It arrests the cell cycle at the G1 phase, promoting cell death and inducing apoptosis by disrupting the mitochondrial membrane potential.

Apoptosis Inducer 29 (compound Y9) demonstrates anticancer efficacy in non-small cell lung cancer by inducing lysosomal dysfunction and apoptosis, and exhibits superior performance to Gboixn both in vitro and in vivo.

Apoptosisinducer 32 (Compound 7g) is an apoptosis inducer with a KD of 42 μM, demonstrating antitumor activity by causing significant morphological changes, such as membrane blebbing, nuclear fragmentation, and apoptotic body formation, in MDA-MB-231 cells. The IC50 values for Apoptosisinducer 32 are 4.77 μM in MCF-7 cells, 6.56 μM in MDA-MB-231 cells, and 337.8 μM in HEK cells.

Ferroptosis/apoptosis inducer-2 (compound D2) is an anticancer drug that has demonstrated anticancer activity both in vivo and in vitro.

Apoptosisinducer 19 (Compound 7g) is an apoptosis inducer. It enhances the expression of pro-apoptotic proteins (Bax and caspase-3) while downregulating anti-apoptotic protein (Bcl-2). Additionally, it increases cellular reactive oxygen species (ROS) levels and disrupts mitochondrial membrane potential (MMP). Apoptosisinducer 19 can be utilized in research on triple-negative breast cancer (TNBC).

Apoptosis inducer39 is an apoptosis inducer with IC50 values of 4.53 μM for MDA-MB-231 cells and 15.42 μM for A549 cells. It exhibits antitumor activity in vitro by reducing the expression of the anti-apoptotic protein Bcl-2 and increasing the expression of the pro-apoptotic protein Bax. Apoptosis inducer39 is applicable in breast cancer and non-small cell lung cancer research.

Apoptosis inducer42 is an apoptosis inducer that triggers late-stage apoptosis and inhibits the secretion of IL-6. It exhibits high cytotoxicity toward cancer cells and is applicable in cancer research, including studies on colon cancer.

Apoptosis inducer40 is an apoptosis (apoptosis) inducer that exhibits potent cytotoxic effects on Jurkat and NB4 cells, with IC50 values of 4.5 μM and 3.6 μM, respectively. It promotes apoptosis and arrests the cell cycle, making it applicable for cancer research, particularly in the study of acute myeloid leukemia (AML).

Apoptosis inducer45 is an apoptosis inducer demonstrating cytotoxic activity against the MCF-7 cell line. It initiates apoptosis in these cells via the mitochondrial pathway by increasing the Bax/Bcl-2 ratio, leading to the cleavage of caspase-9 and subsequent fragmentation of the DNA repair protein PARP. Additionally, Apoptosis inducer45 induces the cleavage of caspase-8, which subsequently triggers the cleavage of caspase-3 and its downstream target PARP, resulting in extrinsic apoptosis. This compound is applicable in breast cancer research.

Apoptosis inducer44 is an apoptosis (apoptosis) inducer. It initiates MDA-MB-231 cell apoptosis by increasing Bax and Cyt C levels, reducing Bcl-2 levels, and activating caspase-3 cleavage. Additionally, Apoptosis inducer44 inhibits the invasion and migration of MDA-MB-231 cells by downregulating MMP-2 and MMP-9 expression and upregulating E-cadherin protein levels. Apoptosis inducer44 is applicable in breast cancer research.

Apoptosis inducer46 is an apoptosis (apoptosis) inducer that exhibits potent and selective growth inhibitory effects on metastatic triple-negative breast cancer (TNBC) cells. It induces G2/M phase cell cycle arrest and apoptosis (apoptosis) cell death in MDA-MB-231 cells and blocks the nuclear translocation of NF-κB. Apoptosis inducer46 is useful for TNBC research.

Apoptosis inducer53 is an apoptosis inducer that inhibits the proliferation of human tumor cell lines (A549, HeLa, SW1573, T-47D, WiDr) with a GI50 value of 2.5-9.1 μM. It induces apoptosis in cancer cells and decreases colony formation. Furthermore, Apoptosis inducer53 activates the p38α MAPK signaling pathway and exhibits anti-inflammatory effects. It also shows activity against the protozoan parasite Leishmania donovani. Apoptosis inducer53 is applicable in research related to cancer, infections, and inflammation.

Apoptosis inducer55 (Compound 10) is an apoptosis inducer that swiftly triggers cell apoptosis through endogenous pathways. It effectively inhibits various signaling pathways, including AKT, ERK1/2, STAT1, STAT3, and S6K. Additionally, Apoptosis inducer55 exhibits anticancer activity against melanoma.

Apoptosis inducer57 is an apoptosis inducer and a thymidylate synthase (TS) inhibitor with cytotoxicity IC50 values of 15.7 µM for SW480 cancer cells and 16.5 µM for MCF-7 cancer cells. It induces dose-dependent apoptosis and S-phase cell cycle arrest. TS-IN-9 stabilizes at the TS active site through interactions with Asp218 and Met311, and is useful for research on breast and colorectal cancers.

Apoptosis inducer 5D is a new type of inducer that induces cell death by activating the apoptosis of cancer cells.

Apoptosis inducer 10 is a potent compound with anti-proliferative activity that induces apoptosis in HeLa (cervical cancer) cells via a mitochondria-dependent endogenous pathway.

Apoptosis inducer 6 is an anticancer agent with broad-spectrum anticancer activity that induces apoptosis, which triggers cell death.

Apoptosis inducer 8 is a galectin-1 (gal-1)-mediated apoptosis inducer and a PET imaging agent that significantly reduces gal-1 protein levels and can be used in major lung cancer studies worldwide.

Apoptosis Inducer 5, a lignan enantiomer extracted from Crataegus pinnatifida, demonstrates cytotoxic properties through inducing apoptosis and autophagy in Hep3B cells.

Apoptosis Inducer 3 (Compound 3), a selective apoptosis triggering agent, induces both apoptosis and late-apoptosis phases, demonstrating cytotoxic effects against cancer cells [1].

Apoptosis Inducer 12 (Compound 3z) is a compound that promotes cell death via the mitochondrial pathway and is utilized in cancer research [1].

Apoptosis Inducer 11 (compound 3u) promotes apoptosis via the mitochondrial pathway and elicits a G2/M block alongside a marked reduction in the S phase within non-Hodgkin lymphoma cell lines [1].

Apoptosis Inducer 13 (Compound Ru4) promotes apoptosis in cancer cells while also suppressing their migration and invasion. Additionally, it facilitates the conversion of coenzyme NADH to NAD+, and elevates intracellular ROS levels [1].